Dicerna Pharmaceuticals Company Profile (NASDAQ:DRNA)

Analyst Ratings

Consensus Ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $14.00 (333.44% upside)

Analysts' Ratings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Chardan CapitalLower Price TargetNeutral$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Stifel NicolausLower Price TargetBuy$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Jefferies GroupReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.84)($0.76)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.78)($0.86)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.73)($0.79)$600.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.57)($0.57)$1.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.63)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014($0.47)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.52)($1.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.92)($0.85)($0.89)
Q3 20162($0.97)($0.94)($0.96)
Q4 20162($1.07)($1.07)($1.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dicerna Pharmaceuticals (NASDAQ:DRNA)
DateHeadline
07/21/16 07:09 AMIncreased Stock Volatility Watch: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
07/21/16 07:09 AMInsiders Increasing Positions in: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Press Telegraph
07/21/16 07:09 AMDicerna Pharmaceuticals Inc. (DRNA) Drops 7.54% on July 19 - Equities.com
07/20/16 07:44 AMBroker Outlook For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Fiscal Standard
07/19/16 08:58 PMHeightened Volatility Spotted on Shares of: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
07/19/16 09:48 AMDicerna Pharmaceuticals Inc. (DRNA) Jumps 5.29% on July 18 - Equities.com
07/16/16 07:06 AMShares Experiencing a Downtrend: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - TGP
07/16/16 07:06 AMIncreased Volatility Noted on Shares of: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
07/16/16 07:06 AMDicerna Pharmaceuticals Inc. (DRNA) Jumps 7.26% on July 15 - Equities.com
07/15/16 06:55 AMCrowd Rating and Earnings Recap for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Telanagana Press
07/14/16 09:09 PMDicerna Pharmaceuticals Inc. (DRNA) Drops 7.04% on July 13 - Equities.com
07/14/16 03:55 PMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 05:18 AMDicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) Shorted Shares Increased By 5.33% - Press Telegraph
07/13/16 03:50 PMShare Volatility Watch for: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
07/13/16 03:50 PMDicerna Pharmaceuticals Inc's Stock Is Sell After Today's Huge Decline - Consumer Eagle
07/13/16 07:58 AMDicerna Pharmaceuticals Inc Stock Momentum Hits Weakness - CML News
07/13/16 07:58 AMWhy Making Dramatic Moves: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), BP p.l.c. (NYSE:BP), Pfizer Inc. (NYSE ... - KC Register
07/13/16 07:58 AMAre Analysts Bullish Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) After Last Week? - Consumer Eagle
07/13/16 07:58 AMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Institutional Investor Positioning - Consumer Eagle
07/11/16 03:42 PMStock Volatility Focus for: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
07/11/16 03:42 PMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 03:02 PMDICERNA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/10/16 03:28 PMDicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) Shorted Shares Increased 5.33% After Market Selling - Press Telegraph
07/07/16 07:46 AMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 03:48 PMIncreased Volatility Watch for: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
07/06/16 03:48 PMStock Rating Watch and Earnings Insight for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Press Telegraph
07/05/16 03:36 PMMorning Alert: Twilio, Inc. (NYSE:TWLO), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Oracle Corporation (NYSE ... - KC Register
06/30/16 03:56 PMChardan Capital covered (NASDAQ:DRNA) Dicerna Pharmaceuticals, lowering its stock price target to $4 today
06/29/16 07:31 AMNew Preclinical Data Show Potential of Dicerna GalXC™ Subcutaneous Delivery Platform as RNAi Drug Discovery Engine - [at noodls] - 2c58128d-4fad-4647-bac3-f0da91835bbb.pdf June 29, 2016 Consistent, Potent and Durable Silencing of Multiple Disease-Driving Genes in Non-Human Primates Reported at Investor Day Initial GalXC Program on ...
06/28/16 08:45 PMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 08:45 PMWere Analysts Bearish Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) This Week? - Press Telegraph
06/28/16 08:45 PMCheck on Share Volatility: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily
06/28/16 08:45 PMDicerna Pharmaceuticals Inc (NASDAQ:DRNA)'s Company Shares Decreased 27.42% After High Volatility - Engelwood Daily
06/24/16 03:47 PMPost Holdings, Inc. (NYSE:POST) increased 3.76%: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), U.S. Bancorp ... - KC Register
06/23/16 02:37 PMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Updated Price Targets - FTSE News
06/23/16 07:20 AMDicerna Pharmaceuticals Inc. (DRNA) Hits New 52-week Low During June 21 Session - Equities.com
06/22/16 03:48 PMDicerna Pharmaceuticals Inc. (DRNA) Hits New 52-week Low During June 20 Session - Equities.com
06/19/16 03:28 PMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 08:46 AMRecently Issued Stock Ratings For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Fiscal Standard
06/15/16 07:23 AMDICERNA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/15/16 06:49 AMDicerna Appoints Martin Freed, M.D., to Board of Directors - [at noodls] - 61dbff45-373f-4f48-b1df-a4a0c58e091d.pdf June 15, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, ...
06/02/16 03:15 PMDicerna to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - ecdcad0e-052a-40bf-941f-da1756b1888d.pdf June 2, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, ...
05/26/16 07:12 PMInsiders Are Gradually Buying Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Hints and News - Insiders Are Gradually Buying Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have increased their position in the stock by 8.78% over the past 6 months. Insiders now own 0.30% of total outstanding shares. There are both legal and ...and more »
05/23/16 06:59 PMStock Rating Review for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Hints and News - Stock Rating Review for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.4 on shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.
05/23/16 06:59 PMDicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7% - Nasdaq - Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%NasdaqDicerna Pharmaceuticals, Inc.DRNA was a big mover last session, as its shares rose almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Friday's rally reverses the recent downtrend for ...Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Quarterly EPS From Continuing Operations Stands At $-0.7601Equities FocusBroker Outlook For The Week Ahead Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)Share Trading Newsall 3 news articles »
05/23/16 07:15 AMDicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7% -
05/19/16 12:10 AMShare Recap and Earnings Focus on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Hints and News - Share Recap and Earnings Focus on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Wall Street Hints and NewsPresently, covering analysts are anticipating Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report quarterly EPS of $-0.87. The company's next earnings report is expected to be released on or around 2016-08-04 for the period ending on 2016-06-30.Buy Calls Count For Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) At 0Enterprise Leaderall 935 news articles »
05/19/16 12:10 AMRevenue Update on Dicerna Pharmaceuticals Inc(NASDAQ:DRNA) - Trade Calls - Revenue Update on Dicerna Pharmaceuticals Inc(NASDAQ:DRNA)Trade CallsDicerna Pharmaceuticals Inc(NASDAQ:DRNA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 9, 2016. Earnings per share were $-0.76. Analysts had estimated an EPS of $-0.86. In a different note, ...
05/16/16 12:23 PMInstitutional Investor's Pro-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Sentiment In Q4 2015 - Wall Street Hints and News - Institutional Investor's Pro-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Sentiment In Q4 2015Wall Street Hints and NewsDicerna Pharmaceuticals Inc (NASDAQ:DRNA) institutional sentiment increased to 1.17 in 2015 Q4. Its up 0.27, from 0.9 in 2015Q3. The ratio is positive, as 27 active investment managers opened new or increased equity positions, while 23 sold and trimmed ...Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Is Trading Up - Insider Trading ActivityFinance Dailyall 2 news articles »
05/14/16 06:28 PMDicerna Pharma (DRNA) Doses First Patient in of DCR-PH1 Phase 1 as PH1 Treatment - Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of ...

Social

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DRNA
  • CUSIP:
Key Metrics:
  • Previous Close: $3.23
  • 50 Day Moving Average: $3.38
  • 200 Day Moving Average: $5.00
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $66.94M
  • Beta: 2.23
  • Current Year EPS Consensus Estimate: $-3.34 EPS
  • Next Year EPS Consensus Estimate: $-2.97 EPS
Additional Links:
Dicerna Pharmaceuticals (NASDAQ:DRNA) Chart for Saturday, July, 23, 2016